NO180375C - Analogifremgangsmåte for fremstilling av terapeutisk aktivt 4-amino-2-(4-n-propylpiperazin-1-yl)-5-(2,3,5-triklorfenyl)pyrimidin - Google Patents

Analogifremgangsmåte for fremstilling av terapeutisk aktivt 4-amino-2-(4-n-propylpiperazin-1-yl)-5-(2,3,5-triklorfenyl)pyrimidin

Info

Publication number
NO180375C
NO180375C NO912100A NO912100A NO180375C NO 180375 C NO180375 C NO 180375C NO 912100 A NO912100 A NO 912100A NO 912100 A NO912100 A NO 912100A NO 180375 C NO180375 C NO 180375C
Authority
NO
Norway
Prior art keywords
hydrogen
halo
amino
alkyl
propylpiperazin
Prior art date
Application number
NO912100A
Other languages
English (en)
Norwegian (no)
Other versions
NO912100L (no
NO180375B (no
NO912100D0 (no
Inventor
Michael John Leach
Malcolm Stuart Nobbs
Ramachandran Iyer
Clive Leonard Yeates
Philip Alan Skone
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of NO912100D0 publication Critical patent/NO912100D0/no
Publication of NO912100L publication Critical patent/NO912100L/no
Priority to NO954109A priority Critical patent/NO954109D0/no
Publication of NO180375B publication Critical patent/NO180375B/no
Publication of NO180375C publication Critical patent/NO180375C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • C07D239/49Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Paper (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
NO912100A 1990-06-01 1991-05-31 Analogifremgangsmåte for fremstilling av terapeutisk aktivt 4-amino-2-(4-n-propylpiperazin-1-yl)-5-(2,3,5-triklorfenyl)pyrimidin NO180375C (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO954109A NO954109D0 (no) 1990-06-01 1995-10-16 Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte 5-arylpyrimidiner

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909012316A GB9012316D0 (en) 1990-06-01 1990-06-01 Pharmacologically active cns compounds

Publications (4)

Publication Number Publication Date
NO912100D0 NO912100D0 (no) 1991-05-31
NO912100L NO912100L (no) 1991-12-02
NO180375B NO180375B (no) 1996-12-30
NO180375C true NO180375C (no) 1997-04-09

Family

ID=10676964

Family Applications (1)

Application Number Title Priority Date Filing Date
NO912100A NO180375C (no) 1990-06-01 1991-05-31 Analogifremgangsmåte for fremstilling av terapeutisk aktivt 4-amino-2-(4-n-propylpiperazin-1-yl)-5-(2,3,5-triklorfenyl)pyrimidin

Country Status (25)

Country Link
EP (2) EP0459819B1 (da)
JP (1) JPH06340634A (da)
KR (1) KR920000733A (da)
AT (1) ATE141263T1 (da)
AU (2) AU652753B2 (da)
CA (1) CA2043640A1 (da)
CZ (1) CZ281070B6 (da)
DE (1) DE69121317T2 (da)
DK (1) DK0459819T3 (da)
ES (1) ES2093078T3 (da)
FI (1) FI912623A (da)
GB (1) GB9012316D0 (da)
GR (1) GR3021237T3 (da)
HU (2) HUT58707A (da)
IE (1) IE911861A1 (da)
IL (2) IL98330A (da)
MY (2) MY136248A (da)
NO (1) NO180375C (da)
NZ (3) NZ248501A (da)
PL (2) PL170373B1 (da)
PT (1) PT97827B (da)
RU (1) RU2091374C1 (da)
SK (1) SK278444B6 (da)
TW (1) TW224460B (da)
ZA (1) ZA914165B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI895821A0 (fi) * 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
MY110880A (en) * 1991-01-30 1999-06-30 The Wellcome Foundation Ltd Water-dispersible tablets
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
GB9226377D0 (en) * 1992-12-18 1993-02-10 Babbedge Rachel C Pharmaceutical compositions
EP0674627A1 (en) * 1992-12-18 1995-10-04 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9319341D0 (en) * 1993-09-17 1993-11-03 Wellcome Found Novel process
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
EP1219609B1 (en) 1999-09-16 2007-04-04 Tanabe Seiyaku Co., Ltd. Aromatic nitrogenous six-membered ring compounds
CN1440393A (zh) 2000-04-28 2003-09-03 田边制药株式会社 环状化合物
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
CA2416442C (en) * 2000-07-24 2010-06-08 Krenitsky Pharmaceuticals, Inc. Substituted 5-alkynyl pyrimidines having neurotrophic activity
KR100540623B1 (ko) 2001-02-26 2006-01-11 다나베 세이야꾸 가부시키가이샤 피리도피리미딘 또는 나프틸리딘 유도체
MXPA04007612A (es) * 2002-02-05 2004-11-10 Novo Nordisk As Aril- y heteroarilpiperazinas novedosas.
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
US8501739B2 (en) 2005-07-04 2013-08-06 High Point Pharmaceuticals, Llc Medicaments
JP2009537596A (ja) 2006-05-23 2009-10-29 ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー 6−(4−シクロプロピルピペリジン−1−イル)−2’−メチル−[3,4’]−ビピリジン及びその医薬としての使用
KR20090040259A (ko) 2006-05-29 2009-04-23 하이 포인트 파마슈티칼스, 엘엘씨 3-(1,3-벤조디옥솔-5-일)-6-(4-시클로프로필피페라진-1-일)-피리다진, 그것의 염과 용매화합물 및 그것의 히스타민 h3 수용체 안타고니스트로서의 용도
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
SG194219A1 (en) * 2011-06-10 2013-11-29 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
WO2017216706A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE518622A (da) *
FI895821A0 (fi) * 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds

Also Published As

Publication number Publication date
IL98330A (en) 1996-10-31
GR3021237T3 (en) 1997-01-31
NZ248501A (en) 1997-03-24
DE69121317D1 (de) 1996-09-19
ES2093078T3 (es) 1996-12-16
MY109958A (en) 1997-10-31
SK278444B6 (en) 1997-05-07
DK0459819T3 (da) 1996-09-02
NO912100L (no) 1991-12-02
IL113599A0 (en) 1995-08-31
KR920000733A (ko) 1992-01-29
IL98330A0 (en) 1992-06-21
EP0459819A2 (en) 1991-12-04
ATE141263T1 (de) 1996-08-15
TW224460B (da) 1994-06-01
FI912623A0 (fi) 1991-05-31
CZ281070B6 (cs) 1996-06-12
HUT58707A (en) 1992-03-30
PL170373B1 (pl) 1996-12-31
HU211649A9 (en) 1995-12-28
NO180375B (no) 1996-12-30
ZA914165B (en) 1993-03-01
EP0459819B1 (en) 1996-08-14
GB9012316D0 (en) 1990-07-18
AU680252B2 (en) 1997-07-24
DE69121317T2 (de) 1997-01-02
AU7809791A (en) 1991-12-05
IE911861A1 (en) 1991-12-04
PT97827A (pt) 1992-03-31
EP0679645A1 (en) 1995-11-02
JPH06340634A (ja) 1994-12-13
IL113599A (en) 1997-09-30
NZ272001A (en) 1997-03-24
AU652753B2 (en) 1994-09-08
RU2091374C1 (ru) 1997-09-27
MY136248A (en) 2008-08-29
NO912100D0 (no) 1991-05-31
HU911826D0 (en) 1991-12-30
NZ238360A (en) 1997-03-24
EP0459819A3 (en) 1992-03-11
PT97827B (pt) 1998-10-30
PL166656B1 (pl) 1995-06-30
FI912623A (fi) 1991-12-02
CS164391A3 (en) 1992-02-19
AU6745594A (en) 1994-09-15
CA2043640A1 (en) 1991-12-02

Similar Documents

Publication Publication Date Title
NO180375C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktivt 4-amino-2-(4-n-propylpiperazin-1-yl)-5-(2,3,5-triklorfenyl)pyrimidin
MD960225A (ro) Compuşi noi cu activitate erbicidă, acaricidă şi insecticidă
YU53700A (sh) Biciklo(2.2.1.) heptani i srodna jedinjenja
FI901982A0 (fi) Menetelmä terapeuttisesti aktiivisten piperatsiniijohdannaisten valmistamiseksi
ES2051723T3 (es) Procedimiento para preparar tetrahidroaminoquinolinoles heterociclicos condensados.
ES8801639A1 (es) Procedimiento para la obtencion de derivados del acido barbiturico
DE3852008D1 (de) Verbindungen.
ATE84028T1 (de) Biologisch aktive verbindungen.
ES8608500A1 (es) Un procedimiento para preparar nuevas 1,2,4-tiadiazinas
SG48687G (en) Imidazolylphenyl amidines
DK0451626T3 (da) Anvendelse af benzodiazepinforbindelser til fremstilling af et farmaceutisk præparat mod med excitatoriske aminosyrer forbundne forstyrrelser i centralnervesystemet
BR8603928A (pt) Compostos de hidrazino-eteres difenilicos,processo para sua preparacao,composicao herbicida e processo para combater o crescimento de plantas indesejaveis
NO954109L (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte 5-arylpyrimidiner
GR3015529T3 (en) Heterocyclic amide derivatives and their use as pesticides.
TH11828EX (th) สารประกอบต่าง ๆ ที่เกี่ยวกับ cns ซึ่งออกฤทธิ์ทางเภสัชวิทยา